Therapeutic antibodies under development for SARS-CoV-2.

View (Beijing, China) Pub Date : 2022-03-01 Epub Date: 2021-07-12 DOI:10.1002/VIW.20200178
Zetong Ma, MengMei Zhu, Shuyi Zhang, Kewen Qian, Chuqi Wang, Wenyan Fu, Changhai Lei, Shi Hu
{"title":"Therapeutic antibodies under development for SARS-CoV-2.","authors":"Zetong Ma, MengMei Zhu, Shuyi Zhang, Kewen Qian, Chuqi Wang, Wenyan Fu, Changhai Lei, Shi Hu","doi":"10.1002/VIW.20200178","DOIUrl":null,"url":null,"abstract":"<p><p>The world is experiencing one of the most difficult moments in history with COVID-19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden. Efforts to fight the virus, including prevention and treatment, have never stopped. However, no specific drugs or treatments have yet been found. Antibody drugs have never been absent in epidemics such as SARS, MERS, HIV, Ebola, and so on in the past two decades. At present, while research on the SARS-CoV-2 vaccine is in full swing, antibody drugs are also receiving widespread attention. Several antibody drugs have successfully entered clinical trials and achieved impressive therapeutic effects. Here, we summarize the therapeutic antibodies against SARS-CoV-2, as well as the research using ACE2 recombinant protein or ACE2-Ig fusion protein.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"3 2","pages":"20200178"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441747/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"View (Beijing, China)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/VIW.20200178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The world is experiencing one of the most difficult moments in history with COVID-19, which has rapidly developed into a worldwide pandemic with a significant health and economic burden. Efforts to fight the virus, including prevention and treatment, have never stopped. However, no specific drugs or treatments have yet been found. Antibody drugs have never been absent in epidemics such as SARS, MERS, HIV, Ebola, and so on in the past two decades. At present, while research on the SARS-CoV-2 vaccine is in full swing, antibody drugs are also receiving widespread attention. Several antibody drugs have successfully entered clinical trials and achieved impressive therapeutic effects. Here, we summarize the therapeutic antibodies against SARS-CoV-2, as well as the research using ACE2 recombinant protein or ACE2-Ig fusion protein.

Abstract Image

Abstract Image

Abstract Image

正在开发治疗 SARS-CoV-2 的抗体。
COVID-19 病毒正迅速发展成为一种世界性流行病,给人们的健康和经济带来沉重负担,世界正经历着历史上最艰难的时刻之一。抗击该病毒的努力,包括预防和治疗,从未停止过。然而,至今仍未找到特效药物或治疗方法。在过去二十年里,SARS、MERS、HIV、埃博拉等流行病从未缺席过抗体药物。目前,在 SARS-CoV-2 疫苗研究如火如荼的同时,抗体药物也受到了广泛关注。一些抗体药物已成功进入临床试验阶段,并取得了令人瞩目的治疗效果。在此,我们总结了针对 SARS-CoV-2 的治疗性抗体,以及使用 ACE2 重组蛋白或 ACE2-Ig 融合蛋白的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信